PDL BioPharma, Inc. P/FCF ratio

P/FCF ratio of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/FCF ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its free cash flow per share. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low P/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current P/FCF ratio of PDL BioPharma, Inc. is 5.48 (as of December 30, 2019)
  • P/FCF ratio for the quarter ending June 29, 2020 was 0.0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly P/FCF ratio decreased by -100.0%
  • Annual P/FCF ratio for 2019 was 5.48 (a -5.52% decrease from previous year)
  • Annual P/FCF ratio for 2018 was 5.8 (a 90.53% increase from previous year)
  • Annual P/FCF ratio for 2017 was 3.04 (a -4.41% decrease from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/FCF ratio of PDL BioPharma, Inc.

Most recent P/FCF ratioof PDLI including historical data for past 10 years.

Interactive Chart of P/FCF ratio of PDL BioPharma, Inc.

PDL BioPharma, Inc. P/FCF ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0 4.65
2019 5.48 3.71 4.4 5.62 5.48
2018 5.8 5.83 4.09 5.61 5.8
2017 3.04 2.98 3.96 5.19 3.04
2016 3.18 3.08 2.59 2.04 3.18
2015 2.52 5.5 3.61 3.89 2.52
2014 3.89 10.95 33.92 18.68 3.89
2013 4.38 4.25 4.32 4.15 4.38
2012 4.63 5.39 4.59 4.5 4.63
2011 5.08 5.01 5.52 5.62 5.08
2010 0.0 0.0 0.0 0.0

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.